Cancer patients experience a considerable number of symptoms during the course of their disease. Of these symptoms, chemotherapy-induced nausea and vomiting (CINV) is one of the most reported and it increases the cancer burden on patients. This study aims to assess the current status of CINV among Jordanian cancer patients, with regard to its incidence and management. A descriptive cross-sectional survey design was used. The study sample was 185 cancer patients. The mean age of participants was 46.6 years (SD = 15.5, range = 18-76) and were mainly female (56.8%). The incidence of nausea and vomiting was high at 71.4% and 57.3%, respectively. Most of the patients (89.7%) received a 5-HT3 antagonist therapy combined with corticosteroids therapy (81.1%). This study demonstrated a high incidence rate of all types of CINV, which was undertreated. Antiemetic treatment could be improved by encouraging nurses to introduce the internationally agreed guidelines into their daily clinical practice.
AaproM.MolassiotisA.DicatoM.PeláezI.Rodríguez-LescureÁ.PastorelliD. (2012). The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Annals of Oncology, 23, 1986-1992.
2.
Al QadireM.Al KhalailehM. (2016). Prevalence of symptoms and quality of life among Jordanian cancer patients. Clinical Nursing Research, 25, 174-191.
3.
AridomeK.MoriS. I.BabaK.YanagiM.HamanoueM.MiyazonoF. (2016). A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Molecular and Clinical Oncology, 4, 393-398.
4.
Bloechl-DaumB.DeusonR. R.MavrosP.HansenM.HerrstedtJ. (2006). Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Journal of Clinical Oncology, 24, 4472-4478.
5.
BrownC. G. (2015). A guide to oncology symptom management. Pennsylvania, United States : Oncology Nursing Society.
6.
ChanA.KimH.-K.HsiehR. K.YuS.de Lima LopesG.Jr.SuW.-C. (2015). Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—A longitudinal analysis. Supportive Care in Cancer, 23, 283-291.
7.
ChungS. K.AhnM. J.YooJ. Y.ChoiM.HyangN.WooS. R. (2011). Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute care setting. International Journal of Evidence-Based Healthcare, 9, 32-38.
8.
GilmoreJ. W.PeacockN. W.GuA.SzaboS.RammageM.SharpeJ. (2014). Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. Journal of Oncology Practice, 10, 68-74.
9.
GonellaS.Di GiulioP. (2015). Delayed chemotherapy-induced nausea and vomiting in the hematology population: A review of the literature. Clinical Journal of Oncology Nursing, 19, 438-443.
10.
Gozzo TdeO.de SouzaS. G.MoysésA. M.PanobiancoM. S.de AlmeidaA. M. (2014). [Incidence and management of chemotherapy-induced nausea and vomiting in women with breast cancer]. Revista Gaúcha de Enfermagem, 35, 117-123.
11.
GrunbergS. M.DeusonR. R.MavrosP.GelingO.HansenM.CrucianiG. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100, 2261-2668.
12.
HawkinsR.GrunbergS. (2009). Chemotherapy-induced nausea and vomiting: Challenges and opportunities for improved patient outcomes. Clinical Journal of Oncology Nursing, 13, 54-64.
13.
HsiehR. K.ChanA.KimH.-K.YuS.KimJ. G.LeeM.-A. (2015). Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Supportive Care in Cancer, 23, 263-272.
14.
LorussoV. (2016). Management of chemotherapy-induced nausea and vomiting by risk profile: Role of netupitant/palonosetron. Therapeutics and Clinical Risk Management, 12, 917.
15.
MolassiotisA.BrearleyS. G.StamatakiZ. (2011). Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Supportive Care in Cancer, 19, 949-956.
16.
MolassiotisA.CoventryP. A.StrickerC. T.ClementsC.EabyB.VeldersL.. . . GrallaR. J. (2007). Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: The MASCC antiemesis tool. Journal of Pain and Symptom Management, 34, 148-159.
17.
MoradianS.HowellD. (2015). Prevention and management of chemotherapy-induced nausea and vomiting. International Journal of Palliative Nursing, 21, 216-224.
18.
NavariR. M. (2009). Pharmacological management of chemotherapy-induced nausea and vomiting. Drugs, 69, 515-533.
19.
RaoK. V.FasoA. (2012). Chemotherapy-induced nausea and vomiting: Optimizing prevention and management. American Health & Drug Benefits, 5, 232-240.
20.
TiptonJ. M.McDanielR. W.BarbourL.JohnstonM. P. (2007). Putting evidence into practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 11, 69-78.
21.
UnderhillM. L.ChickoL.BerryD. L. (2015). A nurse-led evidence-based practice project to monitor and improve the management of chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 19, 38-40.
22.
VidallC. (2011). Chemotherapy induced nausea and vomiting: A European perspective. British Journal of Nursing, 20(Suppl. 5), S22-S28.
23.
VidallC.DielensegerP.FarrellC.LennanE.MuxagataP.Fernández-OrtegaP. (2011). Evidence-based management of chemotherapy-induced nausea and vomiting: A position statement from a European cancer nursing forum. Ecancermedicalscience, 5, 211.
